Bioregnum channel feed – Endpoints News

SIGN UP

Bioregnum channel feed

Exclusive: AstraZeneca signs off on a ‘carbon negative’ new biotech building for one of its latest buyouts

Last week

Did I ever tell you the one about the drunken biotech awards program I hosted at a Chicago bar?

Last week

Astellas builds its R&D footprint in Cambridge/Boston with an add-on for labs, offices

Last month

As SQZ faced a final reckoning, a fateful board decision steered the company to a quick and brutal endgame

2 months ago

The veteran crew at Medicxi is back with a new $400M fund and an upbeat assessment of what's coming

2 months ago

Faheem Hasnain gets a $212M stake together for his big PhIII gamble — here’s why investors are letting it ride

2 months ago

A small Swiss biotech tackles a huge global health issue with a handoff from GSK. But can it make any money from it?

2 months ago

Pfizer, Flagship ally on a $100M cash launch of a drug discovery expedition

2 months ago

Bill Haney adds a matching $100,000 contribution to Kristen Hege's adventurous fundraiser backing women scientists

2 months ago

After ejecting out of Bristol Myers R&D, Rupert Vessey lands at the top science post at a buzzy Flagship

2 months ago

Tessa enjoyed big backers, great science and world-class ambition. So what did we learn from its collapse?

2 months ago

The H1 picture: Biotech’s vital signs show some life — with one big exception

2 months ago

The Endpoints 11 is back: Nominate your favorite biotech for our annual report on the most promising startups in the world

3 months ago

AstraZeneca enlists an upstart China biotech partner in the wake of an R&D setback

3 months ago

Bristol Myers offers a $100,000 vote of support for Kristen Hege's adventurous fundraising campaign

3 months ago

Who's confidently investing in biotech startups during these tense days? We've got some answers

4 months ago

Amit Munshi has more than $300M and a startup CSO out to pioneer next-gen RNA therapeutics. Once again, he’s thinking big

4 months ago

Ex-FDA neuro chief Billy Dunn is taking a spin through the revolving door with biopharma — and that's a problem

4 months ago

The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there's a lot for biotech execs to deal with

4 months ago

When is a preclinical drug worth a mother lode of cash? This top 20 list offers a few answers

4 months ago

Remember that record biotech IPO party in 2018? There was no ‘happily ever after’

4 months ago

In a surprise shift, Tony Coles taps his successor as CEO of Bain startup Cerevel

4 months ago

J&J goes blockbuster hunting (again) with $245M cash upfront for next-gen CAR-T

5 months ago

Another big Vertex challenger suffers a TKO. And that will cause some problems for the CF champ

5 months ago

12 3 4 Next page Last page